Boston Scientific Corporation (NYSE:BSX) registered a 1.92% increase, still its new closing price is 52.33% up from the company’s 1 year high of 24.79.It posted -0.13% losses in previous 5 sessions and is now the subject of 5 analysts who together assign a hold rating on stock. 0 of Wall Street analysts have an underperform rating; the 0 sells versus 10 buy or better ratings. The 25 stock analysts following this company have an average price target at $27.38, with individual PT in the $24.00-$30.00 range. The shares moved at $23.87, implying that brokerage firms see shares gaining about 41.24% in twelve months time.
Boston Scientific Corporation (BSX) SEC Form 4 News
The stock is getting much attention these days as insiders are offloading shares while they posted a 10.36% rise year to date. A SVP and President, Endoscopy at Boston Scientific Corporation (BSX) offloaded shares in a transaction closed on Monday January 09, 2017. Pierce David A sold 10,232 shares in the company at $22.24 each and collected $227,001 in proceeds. Pierce David A now owns 25,600 shares in the company after this transaction. A EVP, GC & Chief Admin Officer in the company, Pratt Timothy A., disclosed a transaction on Monday January 09, 2017 that ended up generating $137,001 from the sale of 6,195 shares at $22.24 per share.
Boston Scientific Corporation (NYSE:BSX) Upcoming Results on Tap
Boston Scientific Corporation will next provide financial results for the March 2017 quarter. Stock analysts expect it to report per-share earnings of $0.31 in that period. Sales during the quarter are predicted to arrive at $2.07 billion.
Earnings surprise history: Last quarter, the company posted approximately $2.11 billion in revenue and EPS of $0.27. The mean forecast was for $2.07 billion and $0.27 a share, respectively. One quarter earlier, revenue for the stock was at $2.13 billion, with earnings at $0.27/share.
Boston Scientific Corporation (BSX) Brokerage Update
Boston Scientific Corporation (BSX) is in Argus’s research list so their analyst rating change is noteworthy. These shares were upgraded to Buy from Hold by Argus, according to news reported on Thursday September 01, 2016.Another important research note was issued by Raymond James on Monday October 05, 2015.The firm upgraded BSX to Strong Buy from Outperform. Over the last six months and over the last three months, the shares of Boston Scientific Corporation (BSX), have changed -1.93% and 8.06%, respectively.
